)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kymera Therapeutics
Kymera Therapeutics (KYMR) investor relations material
Kymera Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
KT-579 Phase 1 showed median IRF5 degradation of at least 90%, broad biomarker effects across immune pathways and placebo-like safety; a lupus Phase 1b study is planned for early 2027.
KT-621 is in Phase 2b trials for atopic dermatitis and asthma; AD results are expected by year-end 2026 and asthma results in late 2027.
Financial highlights
Q3 2026 collaboration revenue was $0, versus $2.764 million in Q3 2025; no additional collaboration revenue is expected in 2026.
Q3 R&D expense was $128.509 million versus $74.094 million; G&A was $18.7 million versus $17.3 million.
Q3 net loss was $131.999 million versus $82.175 million; nine-month net loss was $262.444 million versus $224.370 million.
Nine-month collaboration revenue was $99.365 million versus $36.341 million, reflecting recognized Gilead and Sanofi milestones.
Q3 adjusted cash G&A was $10.8 million, down 14% QoQ; R&D excluding non-cash stock-based compensation was $117.6 million, up 8% QoQ.
Outlook and guidance
KT-621 BROADEN2 AD topline data are expected by year-end 2026; Phase 3 initiation is targeted by mid-2027, subject to supportive data and FDA alignment.
KT-621 BREADTH asthma Phase 2b results are expected in late 2027; KT-579 LUMORA lupus Phase 1b is planned to start by early 2027.
LUMORA is planned as a randomized, double-blind, placebo-controlled 16-week biomarker study in ~30 adults with SLE, allocated 2:1 to KT-579 or placebo.
Gilead is conducting IND-enabling studies for KT-200, with an IND filing planned for 2027; Sanofi leads KT-485 development in Phase 1.
Cash runway is expected to extend into 2029; R&D and G&A expenses are expected to rise as clinical development advances.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kymera Therapeutics
- Early clinical data support oral STAT6 and IRF5 degraders, with key trials ahead.KYMR
Company presentation - Accelerated KT-621 development and broad type 2 disease expansion signal strong pipeline momentum.KYMRStifel 2026 Virtual Immunology and Inflammation Forum
- Accelerated clinical progress in oral immunology therapies sets stage for broad expansion.KYMRWells Fargo 21st Annual Healthcare Conference
- KT-621's clinical progress positions it to transform oral therapy options in atopic dermatitis.KYMRMorgan Stanley 24th Annual Global Healthcare Conference
- STAT6 program advances with phase IIb data expected by year-end, supporting phase III plans.KYMRH.C. Wainwright 28th Annual Global Investment Conference
- Oral immunology therapies targeting STAT6 and IRF5 advance toward key data readouts this year.KYMRCitigroup’s Biopharma Back to School Summit 2026
- Oral degraders advance as transformative therapies for immunology and oncology, targeting major unmet needs.KYMRCorporate presentation
- KT-621 and KT-579 progress rapidly; $65M Q2 revenue, $61.2M net loss, $1.5B cash runway.KYMRQ2 2026
- KT-621 achieved >90% STAT6 degradation, strong Th2 biomarker reduction, and excellent safety.KYMRStudy Result
Next Kymera Therapeutics earnings date
Q4 202625 Feb, 2027
Kymera Therapeutics
Next Kymera Therapeutics earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.